Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADiTx Therapeutics

1.28
-0.0500-3.76%
Post-market: 1.330.0500+3.91%19:58 EDT
Volume:292.02K
Turnover:380.20K
Market Cap:3.11M
PE:0.00
High:1.37
Open:1.31
Low:1.28
Close:1.33
Loading ...

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Business Wire
·
26 Jun

ADiTx Inc. Issues Warrant for 600,000 Shares and Secures Loans from CEO and CIO Totaling $190,000

Reuters
·
26 Jun

The U.S. healthcare company Aditxt has added a "Digital Asset Financial Strategy" to its registration document.

Blockbeats
·
21 Jun

Corrected-Aditxt Inc - Files Prospectus Related to Resale of up to 50 Mln Shares Co May Issue and Sell to Seven Knots From Time to Time - SEC Filing (Adds Dropped Words)

THOMSON REUTERS
·
21 Jun

BRIEF-Aditxt to resale up to 50 million shares to Seven Knots from time to time - SEC filing

Reuters
·
21 Jun

Aditxt Inc - to Resale up to 50 Mln Shares to Seven Knots From Time to Time - SEC Filing

THOMSON REUTERS
·
21 Jun

ADiTx Inc. Files Initial Statement of Beneficial Ownership for Director Saundra Pelletier

Reuters
·
10 Jun

Evofem Biosciences CEO Saundra Pelletier Joins Aditxt Board of Directors to Propel Growth Strategy

Reuters
·
09 Jun

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

THOMSON REUTERS
·
09 Jun

BRIEF-Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6

Reuters
·
05 Jun

Saundra Pelletier, Evofem Biosciences’ CEO, DR. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

THOMSON REUTERS
·
05 Jun

BRIEF-Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt

Reuters
·
30 May

Appili Therapeutics Inc -Entitled to Receive $1 Mln Termination Fee From Aditxt

THOMSON REUTERS
·
30 May

Aditxt to Scrap Merger Deal With Appili Therapeutics

MT Newswires Live
·
19 May

BRIEF-Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics

Reuters
·
19 May

Aditxt Inc. Terminates Arrangement Agreement with Appili Therapeutics, Eliminating $16M in Obligations

Reuters
·
19 May

Aditxt Inc - Termination to Eliminate About $16 Mln in Closing Obligations

THOMSON REUTERS
·
19 May

Aditxt Inc - Termination Effective May 31, 2025

THOMSON REUTERS
·
19 May

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

THOMSON REUTERS
·
19 May

Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01

Reuters
·
15 May